Probiotic Composition Modulating Gut Microbiota for Chemotherapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and radiation, often face challenges in efficacy due to their adverse effects on the immune system and gut microbiota, leading to complications like mucositis and dysbiosis, which can reduce the effectiveness of these therapies.
Innovation Solution
A probiotic composition comprising bacteria such as Enterococcus hirae, Lactobacillus johnsonii, segmented filamentous bacteria, Porphyromonas, Barnesiella, and Holdemania is used as an adjuvant to cancer treatments to modulate the gut microbiota, alongside an antibiotic composition that adjusts the Firmicutes/Bacteroidetes ratio, to enhance the immune response and improve treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is administered to treat cancer, then tumor cells are killed, but the immune system and gut microbiota are adversely affected, leading to reduced treatment efficacy
Solution Approach 1:
The patent applies preliminary action by administering probiotics before chemotherapy treatment to establish a beneficial gut microbiota composition. This pre-treatment approach prepares the immune system and gut environment to better withstand and respond to chemotherapy, thereby improving treatment efficacy while reducing adverse effects on the microbiota
Solution Approach 2:
The patent uses probiotics as an intermediary substance that mediates between chemotherapy and the host's immune system/gut microbiota. The probiotics act as a bridge that modulates the immune response and protects the microbiota from chemotherapy-induced damage, thereby maintaining treatment efficacy while reducing harmful effects
2Object-affected harmful factors
If antibiotics are used to treat chemotherapy-induced infections, then infections are controlled, but gut microbiota dysbiosis is worsened, reducing treatment effectiveness
Solution Approach 1:
The patent converts the harmful effect of antibiotics on gut microbiota into a beneficial outcome by strategically timing antibiotic administration and simultaneously administering specific probiotics. The probiotics compensate for and restore the beneficial microbiota that antibiotics remove, thereby maintaining immune system strength and cancer treatment effectiveness while still controlling infections
3Reliability
If the gut microbiota is altered to enhance immune response, then anticancer immunity is improved, but treatment complexity increases
Solution Approach 1:
The patent applies local quality by targeting specific beneficial bacterial strains (such as Bifidobacterium and Lactobacillus species) rather than attempting to modify the entire gut microbiota ecosystem. This focused approach enhances anticancer immune response through specific probiotic strains while keeping the treatment regimen manageable and clinically feasible
Data Source
AI summary
The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.